Mealey's (November 9, 2016, 5:30 PM EST) -- NEW YORK — A pharmaceutical company and certain of its current and former executive officers misrepresented the company’s business and financial condition to investors and engaged in violations of federal antitrust law by colluding with other generic drug makers to artificially inflate the price of generic drugs in violation of federal securities laws, a shareholder argues in an Oct. 25 complaint filed in New York federal court (Christopher Speakes v. Taro Pharmaceuticals Industries Ltd., et al., No. 16-8318, S.D. N.Y.).

(Complaint available.  Document #57-161121-513C.)

Shareholder Christopher...